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Abstract
Kidney dysfunction in patients with heart failure and cardiovascular disorders in patients with chronic
kidney disease are common. A recently proposed consensus definition of cardiorenal syndrome
stresses the bidirectional nature of these heart-kidney interactions. The treatment of cardiorenal
syndrome is challenging, however, promising new therapeutic options are currently being
investigated in recent and ongoing clinical trials.
Introduction and context
The coexistence of heart failure (HF) and renal dysfunc-
tion, in which the heart and the kidney fail to compensate
for each other’s dysfunction, is very common. About one-
third of the patients with HF have reduced kidney
function that is associated with diuretic resistance and
increased mortality [1]. Another cardiorenal connection is
observed in patients with chronic kidney disease (CKD),
who can have an increased risk of cardiovascular
complications and death [2,3]. Until recently, cardiorenal
syndrome (CRS) was generally defined as an acute or
chronic renal dysfunction resulting from primary changes
in cardiac function. A consensus definition of CRS,
stressing the bidirectional nature of heart-kidney interac-
tions,hasrecentlybeenproposed[4]andwasendorsedby
the Acute Dialysis Quality Initiative group (C Ronco,
personal communication). In addition, increasing
insights into the pathophysiology of this syndrome have
led to promising new therapeutic strategies.
Recent advances
Definition of cardiorenal syndrome
The expanded and refined definition of CRS describes it
as a pathological disorder of the heart and the kidney in
which acute or chronic dysfunction in one organ may
induce acute or chronic dysfunction in the other organ
[4]. It includes five subtypes:
1. CRS type I, or acute CRS, describes the acute kidney
injury resulting from an abrupt worsening of cardiac
function (acute cardiogenic shock or acute decompensa-
tion of congestive heart failure, or CHF).
2. CRS type II, or chronic CRS, describes the progressive
and permanent kidney disease caused by chronic
abnormalities in cardiac function.
3. CRS type III, or acute renocardiac syndrome, describes
an abrupt cardiac disorder that results from an abrupt
worsening of kidney function, mediated by dysregulation
of fluid balance, arrhythmias, or inflammatory mediators.
4. CRS type IV, or chronic renocardiac syndrome, refers to
the decreasedcardiac function, acceleratedatherosclerosis,
left ventricular hypertrophy, and remodeling and/or
increased risk of cardiovascular events in patients with
CKD.
5. CRS type V describes a situation in which a systemic
condition (for example, diabetes or sepsis) causes both
cardiac and renal dysfunction.
Whether this new classification system will increase our
understanding of the pathophysiology or will result in
better therapeutic approaches remains to be proven.
Pathophysiology
The overall understanding of the pathophysiology of
impaired kidney function in patients with cardiac disease
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and relative under-filling of arterial perfusion have been
considered the predominant cause. However, many
clinical studies on this condition have not found an
association between kidney dysfunction and cardiac
output or other hemodynamic parameters, with the
exception of right atrial pressure [5,6], which may point
to an important role of venous congestion and increased
intra-abdominal pressure.
The pathophysiology of CRS is not limited to hemo-
dynamic changes and should be seen as a complex
interplay of neurohumoral activation, which is counter-
productive and maladaptive and results in a vicious circle
with progressive renal dysfunction and worsening HF.
The neurohumoral systems involved are the sympathetic
nervous system (SNS), the renin angiotensin aldosterone
system (RAAS), the endothelin system, and the arginine
vasopressin system. Their activation induces inflamma-
tion and oxidative stress (imbalances between nitric
oxide and reactive oxygen species) and results not only in
vasoconstriction and salt and water retention but also in
accelerated atherosclerosis, cardiac remodeling and
hypertrophy, myocardial and intrarenal fibrosis, and
progression of renal disease [7,8]. Treatment of CRS
relies mainly on interference with this maladaptive
neurohumoral activation.
Treatment
The management of CRS types I and II represents a
clinical challenge. Few agents used in the treatment of
acutely decompensated HF have been shown to improve
clinical outcomes. Many of the current therapies for HF,
such as diuretics, angiotensin-converting enzyme inhibi-
tors (ACEIs), and angiotensin receptor blockers (ARBs),
may have deleterious effects on kidney function, and
aldosterone antagonists are often witheld because of the
fear of hyperkalemia [9,10]. In addition, a majority of
larger trials on the treatment of HF excluded patients
with advanced renal dysfunction.
Diuretics are a vital component of symptomatic manage-
ment of HF. They improve symptoms of acute decom-
pensated HF but have not been shown to improve
long-term morbidity and mortality. Aggressive diuretic
therapy promotes neurohumoral activation and may
worsen CRS. Diuretic resistance is a frequent and
ominous feature of the CRS. Potential therapeutic
strategies include the addition of a thiazide diuretic,
acetazolamide, or spironolactone, or the use of contin-
uousinfusionsofloopdiuretics[7,11].Thelaststrategyis
under investigation in a large multicenter trial [12]. The
combination of hypertonic saline and high doses of
loop diuretics produces a reduction of neurohumoral
activation, significant increases in diuresis and natriuresis,
and reductions in hospitalization time and readmission
rates in patients with refractory CHF [13,14]. The effect of
hypertonic saline on kidney function in patients with
decompensated HF is currently being investigated [15].
An alternative strategy to reduce fluid overload is
ultrafiltration. Compared with diuretics, ultrafiltration
results in increased sodium removal without an increase
of sodium delivery to the distal nephron with activation
of the tubuloglomerular feedback (TGF). Theoretically,
this will result in less activation of the RAAS and the SNS.
The UNLOAD trial compared ultrafiltration with intra-
venous diuretics in patients with acute decompensated
HF. Ultrafiltration induced more weight loss and
reduced rehospitalization rates without a difference in
terms of worsening renal function [16]. A smaller trial
found no difference in fluid balance, glomerular filtra-
tion rate (GFR), and renal plasma flow [17]. The role of
ultrafiltration in patients with CRS is currently being
assessed in a multicenter trial [18]. Other strategies to
improve cardiac output and relieve congestion, such as
cardiac resynchronization therapy, have also been shown
to increase GFR in patients with HF [19].
Interventions that inhibit the activity of the RAAS have
been shown to reduce morbidity and mortality in
patients with HF and to slow or even halt the progression
of CKD, especially diabetic nephropathy [20]. However,
ACEIs and ARBs are underused in patients with CRS
because of the fear of worsening kidney function [21,22].
In patients with moderate renal dysfunction, they appear
to have a survival benefit, despite a transient worsening
of kidney function in as much as 30% of the patients. In
patients with severe renal dysfunction, the trade-off
between efficacy and safety remains unknown, and
cautious use with close monitoring of kidney function
is advised [23]. In view of the risk of hyperkalemia, the
concomitant use of ACEIs or ARBs and aldosterone
antagonists is also problematic in patients with CRS. In
addition, the two large studies on aldosterone antago-
nists in HF have excluded patients with severe renal
failure, and the effect was absent or less pronounced in
those with mild kidney injury [24,25].
Natriuretic peptides induce vasodilation and natriuresis
and decrease neurohormonal levels, the latter in contrast
to diuretics. In addition, they have anti-fibrotic, anti-
hypertrophic, anti-inflammatory, lusitropic, and aldos-
terone-inhibiting properties. Despite symptom relief in
HF, a beneficial effect of nesiritide (a recombinant B-type
natriuretic peptide) on mortality [26,27] could not be
established. Conflicting results with regard to the effect
on kidney function (no effect or worsening) exist
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improvement. The ongoing phase III Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated
Heart Failure Trial (ASCEND-HF) will hopefully provide
a definite answer [31]. Urodilatin is an A-type natriuretic
peptide that can improve symptoms but did not affect
mortality or kidney function in patients with decom-
pensated HF [32].
Newer strategies that target renal function in patients
with HF are adenosine receptor antagonists and vaso-
pressin antagonists. Renal TGF is a normal homeostatic
mechanism to maintain electrolyte and fluid homeo-
stasis. In the setting of HF, the TGF may become
maladaptive and result in diuretic resistance and
decreased GFR [7]. The TGF is mediated through the
adenosine receptor subtype 1 (A1). Blocking this
receptor might enhance diuresis and natriuresis with
maintained or increased GFR and reduce loop diuretic
requirements, as suggested by phase II protocols in
patients with CRS [33-36]. The complexity of adenosine
physiology mandates that safety be established. Larger
phase III trials with these potential new drugs are
ungoing [37].
Blockade of the vasopressin V2 receptor in the collecting
duct results in increased free water excretion, which
theoretically might correct fluid retention and hypona-
tremia in HF. Tolvaptan, an oral selective V2 receptor
blocker, has indeed been shown to result in symptomatic
improvement of patients hospitalized for acute HF,
without worsening kidney function. However, mortality
or HF readmission was not affected [38-40]. Conivaptan
is a dual V1 and V2 receptor blocker that, in addition to
inducing aquaresis, may reduce systemic vascular resis-
tance and improve systolic function [41,42].
Implications for clinical practice
Treatment of CRS relies mainly on interference with
maladaptive neurohumoral activation but remains very
challenging because the traditional treatment of CHF
may have deleterious effects on kidney function.
Investigational drugs targeting the novel pathophysiolo-
gic concepts underlying CRS are promising treatment
approaches. Thiazide diuretics, acetazolamide, or spir-
onolactone, the use of continuous infusions of loop
diuretics, hypertonic saline, and ultrafiltration have
shown promise in overcoming the previous challenges
of aggressive diuretic therapy. Cardiac resynchronization
therapy has been shown to improve GFR in patients with
HF. Although ACEIs and ARBs appear to have some
benefit on survival, the trade-off between efficacy and
safety remains unknown in patients with CRS and
therefore they should be used cautiously and with close
monitoring of kidney function. The adenosine receptor
subtype 1 (A1) and vasopressin antagonists have shown
beneficial effects in improving symptoms for patients
with acute HF. Ongoing trials will define their clinical
efficacy and safety and will hopefully transform the
difficult management of patients with CRS.
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